With FDA approval in sight, why Aerie's keen on global strategy too
November 21, 2017 at 17:20 PM EST
With U.S. Food and Drug Administration approval potentially just around the corner, Aerie Pharmaceuticals (Nasdaq: AERI) has its sights set on global strategy as well.
